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DOI 10.1186/s12944-015-0090-6RESEARCH Open Accessα-linolenic acid and docosahexaenoic acid,
alone and combined with trastuzumab,
reduce HER2-overexpressing breast cancer
cell growth but differentially regulate HER2
signaling pathways
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Background: Diets rich in the n-3 fatty acid alpha-linolenic acid (ALA) have been shown to reduce breast tumor
growth, enhance the effectiveness of the HER2-targeted drug trastuzumab (TRAS) and reduce HER2 signaling in
mouse models. It is unclear whether this is due to direct effects of ALA or due to its long-chain n-3 fatty acids
metabolites including docosahexaenoic acid (DHA).
Methods: The ability of HER2-overexpressing BT-474 human breast cancer cells to convert ALA to long-chain n-3 fatty
acids was determined by measurement of phospholipid fatty acids by gas chromatography following treatment with
100 μM ALA. The effects of 96 h treatment with ALA or DHA, at serum levels seen in mice (50–100 μM), alone and
combined with TRAS (10 μg/ml), on BT-474 cell growth measured by trypan blue exclusion, apoptosis measured by
flow cytometric analysis of Annexin-V/7-AAD stained cells (ALA and TRAS treatment only) and protein biomarkers HER2
signaling measured by western blot were determined.
Results: ALA-treated BT-474 cells had higher phospholipid ALA but no increase in downstream n-3 metabolites
including DHA. Both ALA and DHA reduced cell growth with and without TRAS. ALA had no effect on apoptosis. ALA
and DHA showed opposite effects on Akt and MAPK phosphorylation; ALA increased and DHA decreased
phosphorylation.
Conclusions: Together these data suggest that, while both ALA and its DHA metabolite can reduce HER2-
overexpressing breast cancer growth with and without TRAS, they demonstrate for the first time that DHA is
responsible for the effects of ALA-rich diets on HER2 signaling pathways.
Keywords: Breast cancer, Drug-diet interaction, HER2, Trastuzumab, α-linolenic acid, Docosahexaenoic acidBackground
Dietary approaches to improve breast cancer outcomes
are of interest to the scientific, medical and patient com-
munities [1–3]. n-3 polyunsaturated fatty acids (PUFAs)
have anticancer effects in experimental models and are
commonly consumed by breast cancer patients [3–5]. α-
linolenic acid (ALA, 18:3n-3), found in plant sources
such as nuts and seeds, particularly flaxseed (FS), cannot* Correspondence: lilian.thompson@utoronto.ca
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article, unless otherwise stated.be synthesized in the body. ALA can be metabolized to
the long chain n-3 PUFAs found in fish including eicosa-
pentaenoic acid (EPA; 20:5n-3) and docosahexaenoic
acid (DHA: 22:6n-3). Whether ALA has independent ef-
fects in breast cancer or whether its benefits are due to its
long-chain n-3 PUFAs metabolites remains unclear [6].
This is important to establish because it will lead to better
dietary recommendations for the use of n-3 PUFAs as
complementary treatments in breast cancer.
Animal studies using ALA-rich FS and FS oil (FSO)
diets suggest that plant-based n-3 PUFA sources reducele is distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
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dependent as FS and FSO alone do not affect the growth
of HER2-overexpressing BT-474 tumors in athymic mice
[11, 12]. Interestingly, FSO diets at 4 % [11] and 8 %
[13] levels enhance the effectiveness of the HER2-
targeted drug trastuzumab (TRAS) in reducing tumor
growth and cell proliferation and increasing apoptosis of
BT-474 tumors. This beneficial interaction is at least
partially due to reduced signaling through HER2 as indi-
cated by reduced activation of HER2, Akt and MAPK
[11]. FSO has also been shown to reduce MAPK and
Akt signaling in MCF-7 xenografts [7, 9]. Together, this
suggests that ALA-rich FSO may be a beneficial comple-
mentary treatment approach in breast cancer.
Serum and tumor levels of ALA and long chain n-3
PUFAs EPA and DHA are significantly higher in mice
fed 4 % FSO or 10 % FS diets compared to corn oil-
based basal diets [7, 11, 12, 14]. DHA and DHA-rich fish
oil have demonstrated anticancer effects [15–20] and
have also been shown to affect HER2 signaling [17] in
models of HER2 overexpressing breast cancer. It is
therefore of interest to determine the independent ef-
fects of ALA and DHA at serum levels seen after FSO
feeding and to explore their interaction with TRAS.
It is suggested that breast cancer cell lines lack the
ability to convert ALA to its downstream metabolites,
importantly EPA and DHA due to a lack of Δ6 desatur-
ase enzyme. This has been demonstrated in MCF-7,
MDA-MB-231 and T47D cells where downstream prod-
ucts of reactions catalyzed by of Δ6 desaturase including
gamma linolenic acid, stearidonic acid and DHA were
not produced following treatment with their precursors
linoleic acid, ALA, and EPA, respectively [21–23]. In the
current study we have found for the first time that BT-
474 cells are also unable to metabolize ALA to DHA,
thus presenting a good model to study the independent
effects of ALA and DHA.
Our overall objective was to determine using cell cul-
ture methods whether ALA is the component of FSO re-
sponsible for the effects seen in vivo on HER2 signaling
in BT-474 xenografts. Specifically, we aimed to deter-
mine the effect of ALA with and without TRAS on cell
growth, phospholipid fatty acid profile and protein bio-
markers of HER2 signaling in BT-474 cells. Subse-
quently, the effects of physiologically relevant doses of
the ALA metabolite, DHA, alone and combined with
TRAS, on cell growth and HER2 signaling biomarker ex-
pression were measured. Overall, our findings demon-
strate that both ALA and its DHA metabolite reduce
BT-474 cell growth, however, show for the first time that
only DHA reduces activation of proteins in HER2 signal-
ing pathways. This finding is significant because it em-
phasizes the differences in mechanisms whereby n-3
PUFAs exert their effect in breast cancer.Methods
Cell Line
The BT-474 (HTB-20) cell line was obtained from the
American Type Cell Culture (ATCC; Manassas, VA,
USA) which adheres to the highest ethical standards for
obtaining human tissues. Cells were authenticated by
STR analysis at the Centre for Applied Genomics at the
Sickkids Research Institute (Toronto, ON). Cells were
maintained in RPMI medium (Gibco, Carlsbad, CA,
USA) supplemented with 10 % fetal bovine serum (FBS;
Sigma-Aldrich, St. Louis, MO, USA) and 1 % antibiotic-
antimycotic solution containing penicillin, streptomycin
and amphotericin B (Gibco).Fatty acid and TRAS treatment
ALA and DHA (>99 % pure) were obtained from Sigma-
Aldrich. Stock solutions were prepared in 100 % ethanol,
aliquoted, flushed with nitrogen gas and stored at −20 °C.
In preparation for treatment, ethanol was evaporated with
nitrogen gas. 4 mM solutions were prepared in charcoal-
stripped FBS (CS-FBS; Sigma-Aldrich) and incubated for
1 h at 37 °C to allow for the fatty acids to complex with
albumin in the CS-FBS. TRAS was purchased from the
Princess Margaret Cancer Centre Pharmacy (Toronto,
ON). A 20 mg/ml stock solution of TRAS was prepared
every two weeks using bacteriostatic water and stored
at 4 °C.
Cells in the log phase of growth were plated in tissue
culture plates or flasks (Sarstedt, Numbrecht, Germany)
in RPMI maintenance medium. After approximately
72 h, the medium was removed and replaced with treat-
ment medium. Treatment solutions were prepared using
phenol red-free RPMI 1640 medium (Gibco) containing
1 % antibiotics-antimycotics, 5 % CS-FBS and 1 nM
17β-estradiol (E2; Sigma-Aldrich) dissolved in ethanol.
The control treatment medium contained no fatty acids
or TRAS. TRAS treatment was at 10 μg/ml, a dose com-
monly used in vitro [24, 25] and a target serum trough
concentration in clinical studies [26]. In experiment 1,
cells were treated with ALA (50 and/or 100 μM) alone
and combined with TRAS and cell growth, apoptosis,
phospholipid fatty acids and HER2 signaling protein bio-
markers were measured. In experiment 2, cells were
treated with DHA (50 and 100 μM) alone and combined
with TRAS and cell growth and HER2 signaling protein
biomarkers were measured.
In both experiments, treatment medium was refreshed
after 48 h. To demonstrate that the effect was not simply
due to the addition of fatty acids to the medium, an add-
itional experiment was conducted to confirm the effect
of ALA on cell growth using a background of other fatty
acids (40 μM oleic acid and 40 μM linoleic acid) in both
the control and treatment groups.
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After a total treatment period of 96 h, cells grown in 24
well plates were harvested in 0.25 % trypsin-EDTA
(Sigma-Aldrich). Cell number was counted using the
TC20 automated cell counter (Bio-Rad, Hercules, CA,
USA) based on the trypan blue exclusion assay. The total
live cell number for each well was recorded and the
average of the 3 technical replicates was taken. The ex-
periments were repeated 3–5 times. Results are pre-
sented as a percentage of the untreated control cell
number.
Apoptosis
After 96 h treatment, cells grown in 6 well plates (Sigma)
were collected and washed in phosphate buffered saline
(PBS). Cells were then incubated with 5 μL Annexin V-
APC and 7-AAD stain (BD Biosciences, Mississauga, ON)
for 15 min at room temperature in the dark. Controls
were prepared by adding no stains, Annexin V only and 7-
AAD only. 400 μl of binding buffer (BD Biosciences) was
added to the samples. Samples were immediately analyzed
by flow cytometry using a BD LSR Fortessa. Viable
(Annexin V-/7-AAD-) and apoptotic cells (Annexin V+/7-
AAD- and Annexin V+/7-AAD+) were quantified as a
percent of total cells.
Protein signaling biomarkers
Cells were treated for 48 and/or 96 h and then protein
was extracted using RIPA lysis buffer (Cell Signaling
Technology, Beverley, MA, USA) containing protease in-
hibitors (Complete Mini, EDTA-free Protease Inhibitor
Cocktail Tablets, Roche) and phosphatase inhibitors
(PhosSTOP Phosphatase Inhibitor Cocktail Tablets,
Roche). Protein concentration was measured using the
bicinchoninic acid assay (Thermo Fisher, Ottawa, ON).
Proteins solubilized in Laemmli buffer containing β-
mercaptoethanol (Bio-Rad) were heated for 5 min at 95 °C
and separated in 7.5-10 % polyacrylamide gels (TGX, Bio-
Rad) and transferred to polyvinylidene difluoride mem-
branes. Membranes were blocked with blocking buffer
(5 % BSA or 5 % non-fat dry milk in Tris-buffered saline/
0.1 % Tween-20 (TBS-T), Cell Signaling Technology) for
1 h, washed in TBS-T and then incubated with primary
antibody overnight in a 5 % BSA solution. Primary anti-
bodies included HER2 (CST 2165), pHER2 (CST 4290),
Akt1 (CST 2938), pAkt1 (CST 9018), MAPK (MAPK;
CST 4695), pMAPK (CST 4377), caspase-3 (CST 9665)
and β-actin (CST 3700). After 3 washes in TBS-T, mem-
branes were incubated with anti-rabbit horseradish
peroxidase-conjugated secondary antibody and developed
with LumiGLO® chemiluminescent reagent and peroxide
(Cell Signaling Technology). Signal was detected on X-ray
film (Clonex Corporation, Markham, ON) using a Konica
Minolta™ SRX-101A Film Processor. Band intensity wasquantified using ImageJ Software (National Institutes of
Health, Bethesda). The “relative expression” of each
biomarker was calculated by dividing each sample’s bio-
marker band intensity by its β-actin band intensity
(from stripped and re-probed membrane). The ratios of
phosphorylated to total HER2, Akt1 and MAPK were
calculated as an indicator of HER2 signaling pathway
activation.
Phospholipid fatty acids
After 96 h of treatment, cells were trypsinized, washed
twice in PBS and resuspended in fatty acid free medium.
Total lipids were extracted as described by Bligh and
Dyer [27] using NaCl, methanol and choloform (Sigma-
Alrich) in a 1:2:2 ratio. Thin-layer chromatography was
used to separate lipid classes using silica G-plates (EMD
Chemical, Gibbstown, NJ, USA) Total phospholipid fatty
acids were collected into test tubes and a known amount
of 17:0 standard (Avanti, Alabaster, AL, USA) was added.
Fatty acids were converted to fatty acid methyl esters
(FAME) by incubating for 1 h at 100 °C in hexane and
boron trifluoride-methanol (Sigma-Aldrich). FAME were
transferred to gas chromatography (GC) vials and sam-
ples were analyzed by GC-flame ionization detection
(GC-FID) using a Varian-430 GC (Varian, Lake Forest,
CA, USA) equipped with a Varian FactorFour capillary
column (VF-23 ms; 30 m · 0.25 mm i.d. · 0.25 lm film
thickness) and a FID. Samples were injected in splitless
mode as previously described [28]. Fatty acids were iden-
tified by comparison to a reference standard consisting
of GLC-68 and GLC-455 supplemented with 8:0, 10:0,
and 12:0 methyl esters (Nu-Chek Prep, Elysian, MN)
and quantified by comparing the area of the peaks to the
17:0 peak. Results are presented as mole percentages of
total fatty acids.
Statistical analysis
Statistical analyses were performed using SigmaPlot
(version 12.0; Systat Software Inc., San Jose, CA). Data
are expressed as mean ± SEM. Unpaired t-test was used
to determine differences in phospholipid fatty acids be-
tween control and ALA treated cells. For all other out-
comes, two way analysis of variance was used to
evaluate main effects of fatty acids (ALA or DHA),
TRAS and their interactions. If significant interactions
were observed (P < 0.1), Tukey’s post-hoc test was used
to compare each treatment group with significance set
at P < 0.05.
Results
Experiment 1. Effect of ALA with and without TRAS
Cell growth and apoptosis
TRAS had main effects in reducing cell growth (Fig. 1a)
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Fig. 1 Effect of ALA and TRAS, alone and in combination, on the (a) growth and (b) apoptosis of BT-474 cells. n = 3-5
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ducing cell growth (Fig. 1a). The same growth reduction
results as those shown in Fig. 1 were observed when
ALA was tested on a background of other fatty acids
(data not shown) indicating that it is not simply the
presence of fatty acids that is affecting cell growth. ALA
did not significantly affect the number of apoptotic cells
based on annexin-V staining (Fig. 1b). Since there was a
small but non-significant increase in apoptotic cells in
the ALA treated cells compared to control, caspase 3
protein expression was measured by western blot but no
difference in total or cleaved protein expression was
detected (data not shown).Protein biomarkers of HER2 signaling pathways
Figure 2 shows that pHER2/HER2 expression was not
affected by ALA and TRAS alone and in combination at
48 and 96 h. TRAS significantly reduced pAkt/Akt (48
and 96 h) and pMAPK/MAPK (96 h). ALA treatment
resulted in significantly higher pAkt/Akt and pMAPK/
MAPK at 48 h but had no significant effect at 96 h.
ALAxTRAS interactions were not seen for any bio-
markers at any time point.Phospholipid fatty acid profile
TRAS had no effect on the fatty acid composition of the
cells. Therefore, the results were pooled for cells treated
with 0 uM ALA (control and TRAS) and with 100 μM
ALA (ALA and ALA + TRAS). As seen in Table 1, ALA
treatment caused a dramatic increase in phospholipid
ALA (18:3n-3; 4926 %) but no formation of ALA metab-
olites; in fact, levels of EPA and DHA were significantly
lower in ALA-treated cells.Experiment 2. Effect of DHA with and without TRAS
Cell growth
Both DHA and TRAS showed main effects in reducing
the growth of BT-474 cells (Fig. 3). There was a signifi-
cant DHAxTRAS interaction. Multiple comparisons
showed a significant dose-dependent reduction with
DHA alone. 50 and 100 μM DHA combined with TRAS
significantly reduced cell growth compared to TRAS
alone and there was no significant difference between
the two DHA doses.Protein biomarkers of HER2 signaling pathways
Neither DHA nor TRAS had main effects on pHER2/
HER2 expression nor did they show any interaction
(Fig. 4). Although not statistically significant, there was
45 % lower pHER2/HER2 expression in the DHA100 +
TRAS treated cells compared to TRAS treated cells.
There were significant main effects of TRAS in reducing
the expression of pMAPK/MAPK and pAkt/Akt. DHA
had main effects in reducing pMAPK/MAPK and pAkt/
Akt. DHA + TRAS100 resulted in 27 % lower pMAPK/
MAPK and 56 % lower pAkt/Akt compared to TRAS
alone.Discussion
This study has shown that both ALA and DHA reduce
the growth of BT-474 cells and enhance the effect of
TRAS in reducing cell growth. Our first experiment
showed that BT-474 cells lack the ability to convert ALA
to downstream metabolites thereby presenting a good
system to study the independent effects of ALA and its
metabolite DHA. The results strongly suggest that DHA
reduces growth factor receptor signaling as indicated by



















































































































































Fig. 2 Effect of ALA and TRAS, alone and in combination, on the expression of total and phosphorylated HER2, Akt and MAPK after 48 and 96 h
of treatment of BT-474 cells. (n = 5-6). Representative blots are displayed
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ALA. In vitro ALA treatment reduced phospholipid
DHA level and increased phosphorylation of Akt and
MAPK, thus it is possible that the in vitro effect of ALA
on Akt and MAPK activation is driven by this decrease
in phospholipid DHA. It is important to note that feed-
ing an ALA-rich diet does not decrease but rather in-
creases tumor DHA level in mice [11, 12] suggesting
that this loss of DHA is isolated to in vitro models.
The mechanism driving the growth reducing effect of
ALA in this HER2 overexpressing cell line requires fur-
ther elucidation. Based on the current study, ALA is notacting through an induction of apoptosis or reduction of
HER2 signaling pathways. Although the effect of ALA
on breast cancer cell growth has been previously ex-
plored [7, 21, 29–32], only two studies have looked at ef-
fects on HER2-overexpressing BT-474 cells [33, 34].
Similar to our findings, ALA alone [34, 33] and com-
bined with TRAS (5 μg/ml) [33] reduced BT-474 cell
growth; however, Menendez et al. saw significant reduc-
tions in HER2 mRNA and protein following treatment
with 20 μM ALA in that study. Several, but not all,
studies looking at the effect of ALA in other breast can-
cer cell lines have shown significant growth reductions
Table 1 Phospholipid fatty acid profile of control and ALA-
treated BT-474 cells. Results are presented as molar % of total
fatty acids. N = 6
Control ALA
14:0 2.03 ± 0.62 1.27 ± 1.08
16:0 28.95 ± 4.94 27.16 ± 4.68
18:0 18.11 ± 3.14 17.95 ± 2.62
20:0 0.94 ± 0.21 0.56 ± 0.13
22:0 0.10 ± 0.03a 1.14 ± 0.10b
16:1 n-7 6.97 ± 2.86 6.24 ± 3.55
18:1n-9 16.45 ± 1.03 11.74 ± 1.62
18:1n-7 4.36 ± 0.18a 2.68 ± 0.34b
20:1n-9 0.32 ± 0.08 0.05 ± 0.02
22:1n-9 1.35 ± 0.70a 0.53 ± 0.20b
18:2n-6 4.68 ± 0.86 3.11 ± 0.42
18:3n-6 1.95 ± 0.92 1.15 ± 0.29
20:2n-6 0.35 ± 0.05a 0.18 ± 0.03b
20:4n-6 6.34 ± 0.63a 2.83 ± 0.79b
22:4n-6 0.38 ± 0.05a 0.14 ± 0.02b
22:5n-6 0.08 ± 0.04 0.04 ± 0.01
18:3n-3 0.39 ± 0.15a 19.60 ± 3.60b
20:3n-3 2.64 ± 0.22a 1.09 ± 0.10b
20:5n-3 1.29 ± 0.81 1.14 ± 0.19
22:5n-3 1.18 ± 0.06 0.84 ± 0.17
22:6n-3 1.15 ± 0.12a 0.55 ± 0.14b
n-6:n-3 2.09 ± 0.08a 0.34 ± 0.07b
*values with different superscripts in the same row are significantly different
by unpaired T-test
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a mechanism of ALA effect in MCF-7 cells [29], no such
effect of ALA on apoptosis was seen in BT-474 cells. It
is possible that ALA modulates cell growth through es-
trogen receptor (ER)-related mechanisms. ALA has been





















































Fig. 3 Effect of DHA and TRAS, alone and in combination, on the
growth of BT-474 cells. n = 3receptor and exert mixed agonistic/agonistic effects at
different doses [32]. Dietary FSO reduces the expression
of E2-sensitive genes including progesterone receptor
(PGR) and cyclin D1 in MCF-7 xenografts [9, 35], an ef-
fect that we also have shown with ALA treatment
in vitro in MCF-7 cells (unpublished work). Further re-
search is needed to determine the mechanism for ALA
effect in breast cancer.
More studies have investigated the effect of DHA on
cell growth and apoptosis [16, 18, 22, 31, 36–41]. Others
have similarly found that DHA reduces the growth of
HER2 overexpressing breast cancer cells (BT-474 and
SkBr-3) [17, 18]. Ewaschuk et al. [18] studied the effect
of DHA with and without TRAS on SkBr-3 cells. They
found a 27 % reduction with TRAS treatment alone yet
when 100 μM DHA was combined with TRAS a much
greater reduction was observed (63 %). Similar to our
findings, there was no significant difference between the
cells treated with 100 μM DHA in the absence or pres-
ence of TRAS [18]. Others have suggested that DHA af-
fects cell signaling pathways through incorporation into
membrane rafts thereby affecting the distribution and
activity of associated receptors [22, 36, 38]. DHA has
been fairly consistently shown to induce apoptosis or
affect the expression of markers involved in apoptosis
pathways in breast cancer cells [22, 39, 42–45]. Further-
more, it is well established that treatment with DHA in-
creases phospholipid DHA increases in breast cancer
cells [21, 22, 42]. Apoptosis and fatty acid analysis fol-
lowing DHA treatment was therefore not conducted in
the current study.
We acknowledge several limitations of the current
study. One limitation is that only one ALA metabolite
was studied. EPA is another n-3 ALA metabolite but we
focused specifically on DHA for a number of reasons.
EPA is a minor constituent of tumor and serum fatty
acids [7, 11, 12, 14]. Feeding of 10 % FS or 4 % FSO re-
sulted in serum levels of only 15–22 μM EPA [7, 14]
while studies looking at EPA effect on cell growth
in vitro have seen growth reduction at or above approxi-
mately 100 μM [18, 22, 37]. On the other hand, DHA
concentration in the serum of 10 % FS and 4 % FSO-fed
mice was shown to be 244 and 193 μM [7, 14], respect-
ively, while DHA has been shown to reduce breast
cancer growth at doses as low as 25 μM in HER2-
overexpressing SkBr-3 cells [18]. Furthermore, there was
support for the hypothesis that DHA affects HER2 sig-
naling pathways [16, 17]. An additional limitation is that
only one cell line was used in the current study. How-
ever, literature suggests that the DHA and ALA effects
observed in our study are likely not cell-line specific
since DHA alone has been shown to reduce pAkt in
both BT-474 and SkBr-3 cells [17] and DHA has been































































































































Fig. 4 Effect of DHA (50 and 100 μM) and TRAS, alone and in combination, on the expression of total and phosphorylated HER2, Akt and MAPK
after 96 h of treatment of BT-474 cells. (n = 5-6). Representative blots are displayed. For HER2 protein biomarkers, blot images were cropped and
rearranged for consistency of presentation of treatment groups. Bands for each biomarkers are from the same blot
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that ALA treatment reduces the growth of four breast
cancer cell lines with varying receptor expression [34].
This study was conducted to clarify whether ALA or
its metabolite, DHA, caused the effects seen in vivo
where a diet with ALA-rich FSO significantly enhanced
the effectiveness of TRAS [11]. Therefore, n-3 fatty acid
concentrations used were derived from studies in the
athymic mouse model with feeding of 4 % FS oil or 10 %
FS diets. Serum ALA levels of mice fed these diets
ranged from 33 to 108 μM [7, 14]. Hence, in the current
study, cells were treated with 50 and 100 μM ALA,
levels within this range. In mice fed a 10 % FS or 4 %
FSO diet, approximately 100–150 μM higher serum
DHA was detected compared to mice fed the basal diet.
However we did not treat the cells with 150 uM DHA as
preliminary results from our lab suggested that DHA
treatment higher than 100 μM was cytotoxic. Thus we
treated the cells with 50 and 100 μM. Overall, our find-
ings suggest that treating BT-474 cells with serum levels
of ALA seen in our animal model reduces cell growth
with and without TRAS but does not match the effects
on HER2 signaling pathway markers seen in vivo. On
the other hand, treating BT-474 cells with the concen-
tration of DHA seen following FSO feeding reduces cell
growth and biomarkers of the HER2 signaling pathway
in a similar manner to our in vivo study.
Humans are known to be poor converters of ALA to
DHA and it is suggested that the best way to increase
serum levels of DHA is through dietary intake [46]. Sev-
eral factors are suggested to affect this conversion includ-
ing background fatty acids in the diet and sex [46, 47].
Daily consumption of approximately 6 g of ALA from
FSO for 12 weeks has been shown to increase serum ALA
by approximately 154 μM but increase DHA only by
15 μM [48]. Our findings suggest that interventions that
significantly increase serum DHA are required for modu-
lation of HER2 signaling pathway. Interestingly, a random-
ized controlled trial showed that consumption of 25 g of
FS per day, providing approximately 6 g of ALA, by breast
cancer patients significantly reduced cell proliferation and
HER2 expression [49]. This suggests that despite the low
conversion to DHA in humans, ALA-rich diets may sig-
nificantly reduce breast tumor growth in breast cancer
patients.
The overall objective of this study was to determine
whether ALA is the component of FSO responsible for
the effects seen in vivo on HER2 signaling in BT-474 xe-
nografts. ALA alone did not cause significant downregu-
lation of HER2 signaling while DHA did; therefore, our
findings suggest that the effects of FS and FSO seen in
animal studies on growth factor signaling pathways is
likely due to DHA produced from hepatic conversion of
ALA to DHA and not due to ALA itself. Despite thislack of effect on growth factor receptor signaling, ALA
significantly reduced cell growth perhaps by different
mechanisms including through estrogen receptor signal-
ing, which merits further exploration. Our findings sug-
gest that there are differences in the mechanisms of
ALA and DHA growth effects in HER2 overexpressing
cells. These significant findings contribute to our under-
standing of the role of n-3 PUFAs in breast cancer and
may help in the development of nutritional approaches
for breast cancer treatment.
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